Patients with tumours expressing these oncoproteins will not benefit from targeted therapy directed against BRAF, in particular if paradoxically acting type I1/2 compounds like dabrafenib are involved and the mutational status of RAS proteins or their activators or negative regulators such as NF1 is unknown. This evidence concerns the gene NF1 and neoplasm.